Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Provenzano, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Provenzano, G.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2003; 42: 802-803
© 2003 British Society for Rheumatology

Letters to the Editor

Chronic pulmonary toxicity of methotrexate and rheumatoid arthritis

G. Provenzano

Department of Internal Medicine and Respiratory Diseases, Section of Autoimmune Diseases, A.O. ‘Villa Sofia–CTO’, Palermo, Italy

The first 10% of the full text of this article appears below.

SIR, Methotrexate (MTX) is the most frequently used second-line therapy in rheumatoid arthritis (RA) and is used widely in many other autoimmune disorders. Pulmonary toxicity has been reported in 2–7% of patients receiving low-dose MTX [1], and acute hypersensitivity pneumonitis is the most feared complication [2]. It has also been suggested that chronic pulmonary fibrosis can . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?